Brief: IO Biotech Announces Initiation Of Phase 3 Combination Trial Of IO102-IO103 And Keytruda
18/05/2022 12:27
May 18 (Reuters) - IO Biotech Inc IOBT.O :
* IO BIOTECH ANNOUNCES INITIATION OF PHASE 3 COMBINATION TRIAL OF
IO102-IO103 AND
KEYTRUDA® (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT IN ADVANCED MELANOMA
* IO BIOTECH INC - MULTIPLE SITES TO BE OPENED ACROSS UNITED STATES,
AUSTRALIA,
AND EUROPE
Source text for Eikon: ID:nGNX64Sndj
Further company coverage: IOBT.O
((Reuters.Briefs@thomsonreuters.com;))